Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5508969 | 1.00 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2PIK3CDCHRM2 | |
| SCHEMBL342821 | 1.00 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2PIK3CDCHRM2 | |
| SCHEMBL24337574 | 0.92 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2PIK3CDCHRM2 | |
| SCHEMBL29459509 | 0.92 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2PIK3CDCHRM2 | |
| SCHEMBL17322163 | 0.85 | NR1H2 (0.42) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL30781896 | 0.84 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL28837584 | 0.84 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL28766627 | 0.84 | NR1H2 (0.41) | NR1H2USP2SMN1; SMN2CHRM2CHRM1 | |
| SCHEMBL476249 | 0.83 | PPM1D (0.30) | — | |
| SCHEMBL19408581 | 0.83 | PPM1D (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093660-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | EVOTEC INTERNATONAL GMBH (DE) | 2018-10-09 | — | — | US | disclosed |
| EP-3077383-B1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INT GMBH (DE) | 2018-08-22 | — | — | EP | disclosed |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| EP-3077383-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | Evotec International GmbH (DE) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015082324-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | NR1H2 533/4885USP2 4531/4885SMN1; SMN2 3702/4885 |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, NEK2, SIK2 | NR1H2 1915/4885USP2 3264/4885SMN1; SMN2 279/4885 |
| US-10093660-B2 | Sulfoximine substituted quinazolines for pharmaceutical compositions | NEK5, NEK2, SIK2 | NR1H2 1915/4885USP2 3264/4885SMN1; SMN2 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.